Otsuka adds Phase 3 support for Voyxact in IgA nephropathy

CURRENT FULL VERSION: Otsuka is extending the clinical case for Voyxact, its APRIL-targeting antibody for primary IgA nephropathy, with additional Phase 3 VISIONARY data highlighted around ISN WCN 2026. The backdrop is important: Voyxact already received FDA accelerated approval on November 25, 2025, for reducing proteinuria in adults with primary IgA nephropathy at risk for disease progression, so each new VISIONARY update now serves two purposes, supporting uptake in practice and strengthening the confirmatory package regulators will want to see. (otsuka-us.com)

The story has been building for more than a year. Otsuka first reported positive topline interim results from VISIONARY in October 2024, then presented fuller data in June 2025 showing that sibeprenlimab met the study’s primary endpoint at a pre-specified interim analysis. The trial enrolled 510 adults with biopsy-confirmed IgA nephropathy who were already receiving standard-of-care therapy, defined as maximally tolerated ACE inhibitor and/or ARB treatment, with or without an SGLT2 inhibitor. Patients were randomized to monthly subcutaneous sibeprenlimab 400 mg or placebo. (otsuka.co.jp)

The headline efficacy signal has been consistent across disclosures. Otsuka reported a statistically significant 51% placebo-adjusted reduction in proteinuria at nine months in the interim analysis that supported the FDA filing and later approval. By November 2025, the company said 12-month interim results showed a 54.3% placebo-adjusted reduction in geometric mean 24-hour urine protein-to-creatinine ratio from baseline, along with reductions in APRIL, galactose-deficient IgA1, serum immunoglobulins, and hematuria, plus higher rates of proteinuric remission versus placebo. The NEJM publication indexed in PubMed confirms that these were interim Phase 3 findings from the VISIONARY investigators. (otsuka-us.com)

Mechanistically, Voyxact stands out because it blocks APRIL, a pathway tied to the production of pathogenic galactose-deficient IgA1 in IgA nephropathy. Otsuka has repeatedly framed that as a way to intervene upstream in disease biology rather than only manage downstream manifestations. That mechanism helped differentiate Voyxact when FDA granted accelerated approval, and outside coverage described it as the first approved APRIL inhibitor for adults with primary IgA nephropathy at risk for progression. (otsuka-us.com)

Expert reaction has generally been favorable, though still cautious about the need for hard renal outcomes. In Otsuka-circulated comments, Dana Rizk, MD, a VISIONARY investigator and steering committee co-chair, said Voyxact is the first approved treatment in this population to block APRIL. Nephrology commentary has also treated VISIONARY as one of the more important recent developments in the field, with NephJC listing it among the top nephrology stories of 2025 and emphasizing the biologic effects on disease-driving markers. (appliedclinicaltrialsonline.com)

Why it matters: Although this is a human drug development story rather than a veterinary therapeutic one, it’s still relevant to veterinary professionals who track translational immunology, monoclonal antibody development, and regulatory strategy around surrogate endpoints. VISIONARY is a case study in how a biologic can move from mechanistic rationale to accelerated approval on proteinuria reduction, while the sponsor continues blinded follow-up for kidney function outcomes. For readers watching comparative nephrology, immune-mediated renal disease, or the broader biologics market, Otsuka’s progress also shows how specialty renal pipelines are shifting toward targeted immunomodulation. (otsuka.co.jp)

The commercial context matters, too. IgA nephropathy has become a more crowded treatment category, with sparsentan and budesonide already holding full FDA approvals tied to slowing kidney function loss in adults with IgA nephropathy, according to specialty coverage. That means Voyxact’s long-term positioning may depend less on proving proteinuria reduction, which it has already done, and more on whether the 24-month eGFR data show a clinically persuasive renal benefit and how safety, convenience, and sequencing play out in practice. More broadly, the Voyxact updates are arriving as Otsuka is also deploying capital elsewhere in its pipeline: the company, through Otsuka America, has agreed to acquire Transcend Therapeutics for $700 million upfront plus about $525 million in sales milestones, for a total potential value of roughly $1.225 billion. That deal, expected to close in Q2 2026, would add TSND-201 (methylone), a Phase 3-ready PTSD candidate with U.S. patient recruitment underway, along with novel prodrug programs intended to improve efficacy, safety, and tolerability, with a lead candidate already selected and nonclinical work ongoing toward an FDA IND filing. (hcplive.com)

What to watch: The next major catalyst is the confirmatory kidney function readout from VISIONARY, which Otsuka says is expected in 2026; that dataset is likely to shape labeling, reimbursement, competitive standing, and whether accelerated approval is converted to full approval. In parallel, the expected Q2 2026 close of the Transcend acquisition will be worth watching as another marker of Otsuka’s broader growth strategy across renal, psychiatric, and neurological indications. (otsuka.co.jp)